An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment
- 1 April 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 115 (4) , 791-796
- https://doi.org/10.1016/j.jaci.2005.01.040
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Targeting Syk as a treatment for allergic and autoimmune disordersExpert Opinion on Investigational Drugs, 2004
- The effect of a novel inhibitor of mast cell activation on mediators, symptoms and nasal patency in allergic rhinitis*1Journal of Allergy and Clinical Immunology, 2004
- Design and Synthesis of Non-peptidic Inhibitors for the Syk C-Terminal SH2 Domain Based on Structure-Based In-Silico ScreeningJournal of Medicinal Chemistry, 2001
- Allergic Rhinitis and Its Impact on AsthmaJournal of Allergy and Clinical Immunology, 2001
- Onset of therapeutic effect of fluticasone propionate aqueous nasal sprayAnnals of Allergy, Asthma & Immunology, 2001
- Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitisAnnals of Allergy, Asthma & Immunology, 1999
- Mometasone Furoate Nasal Spray is Rapidly Effective in the Treatment of Seasonal Allergic Rhinitis in an Outdoor (Park), Acute Exposure SettingAllergy and Asthma Proceedings, 1999
- Joint Task Force Algorithm and Annotations for Diagnosis and Management of RhinitisAnnals of Allergy, Asthma & Immunology, 1998
- Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 1996